^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Intestinal Carcinoma |
| Regimen: | FOLFIRI (5-fluorouracil + irinotecan + leucovorin calcium) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
FOLFIRI is recommended as a treatment option for second- or subsequent-line treatment of advanced SBA.
